BioCardia (BCDA) Registration Filing summary

Company overview and business model

• Clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases with significant unmet needs.

• Two cell therapy platforms in clinical trials: CardiAMP (autologous) for ischemic heart failure and refractory angina, and CardiALLO (allogeneic) for ischemic heart failure and ARDS.

• Proprietary Helix minimally invasive delivery platform supports both in-house and partnered biotherapeutic programs.

Financial performance and metrics

• History of operating losses and ongoing need for substantial additional financing to achieve development and commercialization goals.

• Net proceeds from the offering estimated at $5.3 million, with potential for up to $6.6 million more if all warrants are exercised.

• As of June 30, 2024, cash and equivalents were $2.9 million; pro forma for the offering, $8.2 million.

• Immediate dilution to new investors of $1.97 per share based on the assumed offering price.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes, including advancing investigational biotherapeutic candidates and delivery partnering business.

• No specific allocation to debt repayment, redemptions, or litigation settlements.